EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Prognostic value of miR-21 in colorectal cancer, pancreatic ductal adenocarcinoma, and esophageal squamous cell carcinoma: updated systematic review and meta-analysis

Jing Huang, Qiang He, Jufang Wang, Chunbao Zhai iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf309 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Oncologist, 2025. Verfasst von Jing Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, The Shanxi Province People's Hospital, Taiyuan, China. Hauptthemen laut MEDLINE: MicroRNAs, Carcinoma, Pancreatic Ductal, Esophageal Squamous Cell Carcinoma, Pancreatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aims to conduct a systematic review of the prognostic value of miR-21 expression levels in patients with colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and esophageal squamous cell carcinoma (ESCC). Methods and Results We searched the PubMed, Embase, and CENTRAL databases for relevant studies published up to August 25, 2023. Sixteen studies, totaling 3096 patients, were included. High miR-21 expression was associated with higher hazard ratio (HR) values and decreased overall survival (OS) in CRC and PDAC, but this effect was not statistically significant in ESCC. The pooled HRs for CRC, PDAC, and ESCC were 1.54 (95% confidence interval [CI]: 1.14-2.07; P = 0.004; I2 = 71%), 2.11 (95% CI: 1.81-2.46; P < 0.001; I2 = 0%), and 1.79 (95% CI: 0.82-3.92; P = 0.15; I2 = 75%), respectively. Patients with high miR-21 expression had higher HR values and decreased disease-free survival (DFS) compared to those with low miR-21 expression in all three cancer types. The pooled HRs for CRC, PDAC, and ESCC were 1.88 (95% CI: 1.36-2.60; P < 0.001; I2 = 59%), 2.04 (95% CI: 1.34-3.11; P < 0.001; I2 = 17%), and 1.77 (95% CI: 1.04-3.03; P = 0.04; I2 = 36%), respectively.

Conclusion

Elevated miR-21 expression levels are associated with poorer OS and DFS in patients with CRC, pancreatic cancer, and esophageal cancer. However, due to heterogeneity in the results, further large-sample, high-quality studies are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsCarcinoma, Pancreatic DuctalEsophageal Squamous Cell CarcinomaPancreatic NeoplasmsColorectal NeoplasmsEsophageal NeoplasmsHumansPrognosisBiomarkers, Tumor

Stichwörter der Autor:innen

colorectal canceresophageal squamous cell carcinomamicroRNA-21pancreatic ductal adenocarcinomaprognosis

Substanzen

MicroRNAsMIRN21 microRNA, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Colorectal Surgery, The Shanxi Province People's Hospital, Taiyuan, China.
  • Department of Ultrasound Medicine, The Shanxi Province People's Hospital, Taiyuan, China.

ORCID-Profile: Chunbao Zhai

Zitieren

APA

Huang, J., He, Q., Wang, J., & Zhai, C. (2025). Prognostic value of miR-21 in colorectal cancer, pancreatic ductal adenocarcinoma, and esophageal squamous cell carcinoma: updated systematic review and meta-analysis. The Oncologist. https://doi.org/10.1093/oncolo/oyaf309

Vancouver

Huang J, He Q, Wang J, Zhai C. Prognostic value of miR-21 in colorectal cancer, pancreatic ductal adenocarcinoma, and esophageal squamous cell carcinoma: updated systematic review and meta-analysis. The Oncologist. 2025. doi:10.1093/oncolo/oyaf309

BibTeX
@article{Huang2025,
  author = {Huang, Jing and He, Qiang and Wang, Jufang and Zhai, Chunbao},
  title = {Prognostic value of miR-21 in colorectal cancer, pancreatic ductal adenocarcinoma, and esophageal squamous cell carcinoma: updated systematic review and meta-analysis},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf309}
}
Kostenlos starten →